tolvaptan has been researched along with Chemical and Drug Induced Liver Injury in 20 studies
*Chemical and Drug Induced Liver Injury: A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 12 (60.00) | 24.3611 |
| 2020's | 8 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Alpers, DH; Estilo, A; Freston, JW; Hoke, ME; Hunt, CM; Lewis, JH; Li, H; Roth, SE; Torres, VE; Wang, W; Westcott-Baker, L | 1 |
| Annicchiarico Petruzzelli, L; Pellegrino, AM; Pisani, A; Riccio, E | 1 |
| Howell, BA; Pellegrini, L; Shoda, LKM; Woodhead, JL | 1 |
| Beaudoin, JJ; Brock, WJ; Brouwer, KLR; Watkins, PB | 1 |
| Dixon, D; Fallon, JK; Liu, J; Mosedale, M; Nautiyal, M; Qasem, RJ; Smith, PC; Wolf, KK | 1 |
| Gibson, A; Hammond, S; Jaruthamsophon, K; Mosedale, M; Naisbitt, DJ; Roth, S | 2 |
| Chapman, AB; Devuyst, O; Estilo, A; Gansevoort, RT; Hoke, ME; Lee, J; Perrone, RD; Sergeyeva, O; Torres, VE | 1 |
| Imai, S; Kashiwagi, H; Miyai, T; Momo, K; Sato, Y; Sugawara, M; Takekuma, Y | 1 |
| Bando, K; Ito, K; Nakagawa, T; Ogimura, E; Sekine, S; Tokizono, M | 1 |
| Beaudoin, JJ; Bezençon, J; Brock, WJ; Brouwer, KLR; Cao, Y; Mizuno, K; Roth, SE | 1 |
| Giuliani, C; Peri, A | 1 |
| Hensen, J | 1 |
| Alpers, DH; Blais, JD; Czerwiec, FS; Kaplowitz, N; Krasa, H; Lewis, JH; Ouyang, J; Smotzer, DM; Torres, VE; Watkins, PB; Zimmer, CA | 1 |
| Brock, WJ; Brouwer, KL; Brouwer, KR; Freeman, KM; Lu, Y; Pan, M; Slizgi, JR; St Claire, RL | 1 |
| Brock, WJ; Brouwer, KL; Church, R; Grammatopoulos, TN; Howell, BA; Mosedale, M; Roth, SE; Shoaf, SE; Shoda, LK; Siler, SQ; Stiles, L; Watkins, PB; Woodhead, JL | 1 |
| Brock, WJ; Corty, RW; Eaddy, JS; Keele, GR; Kim, Y; Mosedale, M; Roth, SE; Valdar, W; Watkins, PB; Wiltshire, T; Xie, Y | 1 |
| Howell, BA; Shoda, LKM; Siler, SQ; Watkins, PB; Woodhead, JL | 1 |
3 review(s) available for tolvaptan and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Management of euvolemic hyponatremia attributed to SIADH in the hospital setting.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blood Volume; Body Water; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Demeclocycline; Diabetes Insipidus, Nephrogenic; Disease Management; Drug Interactions; Hospitalization; Humans; Hydrocortisone; Hyponatremia; Hypothyroidism; Inappropriate ADH Syndrome; Kidney Tubules, Collecting; Lithium; Multicenter Studies as Topic; Osmolar Concentration; Paraneoplastic Syndromes; Saline Solution, Hypertonic; Tolvaptan | 2014 |
The role of quantitative systems pharmacology modeling in the prediction and explanation of idiosyncratic drug-induced liver injury.
Topics: Animals; Benzazepines; Chemical and Drug Induced Liver Injury; Chromans; Drug-Related Side Effects and Adverse Reactions; Humans; Models, Biological; Thiazolidinediones; Tolvaptan; Troglitazone | 2017 |
1 trial(s) available for tolvaptan and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
Topics: Adult; Alanine Transaminase; Antidiuretic Hormone Receptor Antagonists; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Female; Humans; Male; Middle Aged; Polycystic Kidney, Autosomal Dominant; Prospective Studies; Time Factors; Tolvaptan | 2020 |
16 other study(ies) available for tolvaptan and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials.
Topics: Alanine Transaminase; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Chemical and Drug Induced Liver Injury; Humans; Polycystic Kidney, Autosomal Dominant; Prospective Studies; Retrospective Studies; Tolvaptan | 2023 |
Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report.
Topics: Adult; Alanine Transaminase; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Antidiuretic Hormone Receptor Antagonists; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Liver; Polycystic Kidney, Autosomal Dominant; Tolvaptan | 2019 |
Comparison of the Hepatotoxic Potential of Two Treatments for Autosomal-Dominant Polycystic Kidney DiseaseUsing Quantitative Systems Toxicology Modeling.
Topics: Benzamides; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adverse Reactions; Humans; Models, Theoretical; Polycystic Kidney, Autosomal Dominant; Pyrroles; Tolvaptan | 2020 |
Quantitative Systems Toxicology Modeling Predicts that Reduced Biliary Efflux Contributes to Tolvaptan Hepatotoxicity.
Topics: Bile Acids and Salts; Biological Transport; Cell Line, Tumor; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adverse Reactions; Hepatocytes; Humans; Liver; Polycystic Kidney, Autosomal Dominant; Tolvaptan | 2021 |
Characterization of primary mouse hepatocyte spheroids as a model system to support investigations of drug-induced liver injury.
Topics: Acetaminophen; Adenosine Triphosphate; Albumins; Animals; Arabinofuranosyluracil; Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme System; Female; Hepatocytes; Male; Mice, Inbred C57BL; Models, Biological; Phenylacetates; Proteomics; Spheroids, Cellular; Sulfonamides; Tolvaptan; Transcriptome | 2021 |
Shedding Light on Drug-Induced Liver Injury: Activation of T Cells From Drug Naive Human Donors With Tolvaptan and a Hydroxybutyric Acid Metabolite.
Topics: Antidiuretic Hormone Receptor Antagonists; Chemical and Drug Induced Liver Injury; Humans; Leukocytes, Mononuclear; Pharmaceutical Preparations; Polycystic Kidney, Autosomal Dominant; T-Lymphocytes; Tolvaptan | 2021 |
Tolvaptan- and Tolvaptan-Metabolite-Responsive T Cells in Patients with Drug-Induced Liver Injury.
Topics: Adult; Cell Proliferation; Chemical and Drug Induced Liver Injury; Female; Humans; Male; Middle Aged; Molecular Structure; T-Lymphocytes; Tolvaptan | 2020 |
A cross-sectional survey of hospitalization and blood tests implementation status in patients who received tolvaptan under 75 years of age using a Japanese claims database.
Topics: Antidiuretic Hormone Receptor Antagonists; Chemical and Drug Induced Liver Injury; Cross-Sectional Studies; Databases, Factual; Female; Heart Failure; Hematologic Tests; Hospitalization; Humans; Hypernatremia; Japan; Liver Function Tests; Male; Middle Aged; Sodium; Tolvaptan | 2021 |
Metabolic Activation of Cholestatic Drug-Induced Bile Acid-Dependent Toxicity in Human Sandwich-Cultured Hepatocytes.
Topics: Activation, Metabolic; Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Bile Acids and Salts; Biological Transport; Cells, Cultured; Chemical and Drug Induced Liver Injury; Cholestasis; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Hepatocytes; Humans; Male; Rats; Rats, Sprague-Dawley; Tolvaptan; Toxicity Tests; Triazoles | 2017 |
Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Hepatobiliary Elimination; Humans; In Vitro Techniques; Kidney; Liver; Male; Perfusion; Polycystic Kidney, Autosomal Dominant; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Receptors, Cell Surface; Tolvaptan | 2019 |
[Hyponatremia and tolvaptan : what is the situation 5 years after approval?].
Topics: Benzazepines; Chemical and Drug Induced Liver Injury; Diuretics; Drug Approval; Evidence-Based Medicine; Germany; Hypernatremia; Hyponatremia; Risk Assessment; Tolvaptan; Treatment Outcome | 2015 |
Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database.
Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Chemical and Drug Induced Liver Injury; Databases, Factual; Female; Humans; Male; Middle Aged; Polycystic Kidney, Autosomal Dominant; Randomized Controlled Trials as Topic; Retrospective Studies; Statistics as Topic; Tolvaptan | 2015 |
Inhibition of Human Hepatic Bile Acid Transporters by Tolvaptan and Metabolites: Contributing Factors to Drug-Induced Liver Injury?
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Carrier Proteins; Chemical and Drug Induced Liver Injury; CHO Cells; Cricetulus; Hepatocytes; Humans; Membrane Glycoproteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Polycystic Kidney, Autosomal Dominant; Taurocholic Acid; Tolvaptan | 2016 |
Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Chemical and Drug Induced Liver Injury; Disease Susceptibility; Humans; Models, Biological; Tolvaptan | 2017 |
Editor's Highlight: Candidate Risk Factors and Mechanisms for Tolvaptan-Induced Liver Injury Are Identified Using a Collaborative Cross Approach.
Topics: Animals; Benzazepines; Biomarkers; Chemical and Drug Induced Liver Injury; Immunity, Innate; Liver Function Tests; Mice, Inbred Strains; Oxidative Stress; Risk Factors; Species Specificity; Tolvaptan; Toxicogenetics; Transcriptome | 2017 |